Sharp Edge Labs, Inc., http://www.sharpedgelabs.com a drug discovery biology firm, and Creagen Biosciences Inc. http://www.creageninc.com a medicinal chemistry firm, today announced that they have entered into a compound library screening agreement to test Creagen’s medicinal chemistry compound libraries in Sharp Edge Labs’ biological screening assays. The agreement covers all libraries in the Creagen collection and will be applied to Sharp Edge Labs screening assays across therapeutic areas, including, Parkinson’s, Alzheimer’s, Cancer, Cystic Fibrosis and Lysosomal Storage Disorders.
Scott Sneddon, PhD, J.D., President and CEO of Sharp Edge Labs noted that this was a unique opportunity to bring Creagen’s compounds into Sharp Edge Labs’ trafficking assays, and to probe previously unexploited miolecular mechanisms for these diseases. The agreement is open-ended, with additional compounds being made available and additional screening assays being offered by agreement of the companies. “We’re excited to test Creagen’s compounds across a portfolio of first-in-class cellular trafficking assays using our technology’” Sneddon said. “These assays probe novel biology, and expose molecular targets not previously exploited in drug discovery programs.” Sneddon said. Prior to co-founding Sharp Edge Labs, Sneddon was part of the Drug Discovery program at Genzyme Corp., where he oversaw numerous similar compound library screening collaborations.
March 24, 2014, The State Room, Boston, MA
CreaGen Biosciences and CreaGen Chemistry Incubator (C2I) are sponsors of the Redefining Early Stage Investments, a quarterly ongoing conference series that will be establishing a global circuit for early stage life sciences companies to source investors, create relationships, and eventually, get funding. These events will give early stage life science companies the chance to start, resume or close conversations with relevant investors, creating a global dialogue to bring products to market at a faster pace. Visit CreaGen Biosciences and CreaGen Chemistry Incubator (C2I) booth at this event to learn more about our services and facility. http://www.resiconference.com
Thursday – December 12th, 2013 Sponsored and Hosted by Genzyme, a Sanofi Company; Raj Rajur, Ph.D., NESAC Medicinal Chemistry, Chair.
Rajur, Ph.D. , Chairman & CEO, CreaGen Bioscience was Co-Chair of the Second Annual Massachusetts CRO/CMO Symposium CreaGen Biosciences will be one of the 40+ companies exhibiting at the February 25th event that showcases the local service providers from the greater MA life sciences cluster
May 5, 2014, Burlington Marriott, Burlington, MA
Raj Rajur, Ph.D. , Chairman & CEO, CreaGen Bioscience is a member of the Event Steering Committee and is Co-chair of MassBio’s CRO CMO Form. CreaGen Biosciences will be one of the 40+ companies exhibiting at the event that showcases the local service providers from the greater MA life sciences cluster. More Details
Symposium Presented by MassBio’s Massachusetts CRO CMO Committee Symposium featured an address by Tim Murray, Lieutenant Governor State of Massachusetts The Conference Center at Bentley University, 75 Forest Street, LaCava 300, Waltham, MA 02452
Date/Location: held on April 9, 2010 at the Royal Sonesta Hotel in Cambridge, MA. co-sponsored in part by CreaGen Biosciences, Inc
“New Developments in RNAi Therapeutics” Date/Location: December 10th, 2009 at the Marriott Hotel, Burlington, MA
“Frontiers in Strategies and Technologies to enrich pharmaceutical pipelines” held on May 21-22, 2009, Merck Research Laboratories Boston Amphitheater, Boston, MA. was Hosted and co-sponsored in part by CreaGen Biosciences, Inc.